Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study

BACKGROUND/AIMS: ONO-9054 is being developed for the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OHT) and open-angle glaucoma (OAG). This study compared the novel dual EP3/FP agonist ONO-9054 with the FP agonist Xalatan. METHODS: Adults (n=123) with bilateral mild/m...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller Ellis, Eydie, Berlin, Michael S, Ward, Caroline L, Sharpe, John A, Jamil, Alam, Harris, Alon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583686/
https://www.ncbi.nlm.nih.gov/pubmed/27649982
http://dx.doi.org/10.1136/bjophthalmol-2016-309023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583686/
https://www.ncbi.nlm.nih.gov/pubmed/27649982
http://dx.doi.org/10.1136/bjophthalmol-2016-309023

Ejemplares similares